Jongo Said Abdallah

In the News

IHI chief: Hub for innovative minds in the pipeline

(Dar es Salaam) Ifakara Health Institute (IHI) Chief Executive Director Dr. Honorati Masanja has unveiled plans to establish an innovation hub in the Institute’s birthplace – Ifakara. IHI Chief Executive …

Scientists challenged to go beyond journal publications

(Dar es Salaam) The Deputy Minister for Health, Community Development, Gender, Elderly and Children, Dr. Faustine Ndugulile, has urged scientists to consider taking their study results documented in journals a …

Recent Projects

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Jongo Said Abdallah

Research Scientist and Head of Clinical Trials Facility

Dr. Jongo Said Abdallah is a Physician specialized in Internal medicine and the head of theIHI  Clinical Trials Unit. As a senior research scientist his scientific knowledge and clinical expertise cut across the spectrum from the diagnosis, treatment and care to conducting advanced clinical research and managing clinical trials. He is leading a team of scientists and non-scientists in designing and conducting phase 1 to phase 3 Good Clinical Practice (GCP) compliant studies as well as analysis and reporting for regulatory review and licensure. His work is focused on conducting high quality clinical trials on the diseases of public health importance, mainly focusing on malaria and non-communicable diseases. His malaria research involvement include; the assessment of safety and efficacy of novel antimalarials  and transmission blocking potential as well as models for prevention; assessment of safety and efficacy for novel Good Manufacturing Practice (GMP) certified malaria vaccine candidates for malaria control and elimination; and mechanism for efficient  translation of research results into policy improvement and community well-being. He is an active member of the International Plasmodium falciparum Sporozoite Consortium (I-PfSPZ-C), and is actively involved in mapping out the clinical development pathway for the PfSPZ-based vaccines, in which thirty-seven research groups in 15 countries, are collaborating to advance candidate vaccines based on injectable Plasmodium falciparum (Pf) sporozoites (SPZ). He is currently, the principal investigator for the “Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants” in which the safety of the PfSPZ vaccine is being assessed for the first time in the world in pediatric population including infants from 6 months old and the efficacy for higher doses of PfSPZ vaccine is being assessed in African adult population.

View Dr. Jongo’s Research Interests & Publications


Evaluation of whole sporozoite vaccines for malaria elimination

Safety and immunogenicity of direct venus inoculation of Plasmodium falciparum sporozoite vaccine in adults, children and infants

Safety, immunogenicity and efficacy of intravenously administered attenuated Plasmodium falciparum sporozoite vaccine

© Ifakara Health Institute (IHI), 2016